Status:
RECRUITING
Study to Understand Novel Biomarkers in Researching Dementia
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Alzheimer Disease
Mild Cognitive Impairment
Eligibility:
All Genders
60+ years
Brief Summary
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cogniti...
Detailed Description
All participants who are eligible and provide informed consent will complete an initial study visit, which includes a research blood collection and cognitive assessments. Depending on the results of t...
Eligibility Criteria
Inclusion
- At least 60 years of age
- 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider
- All SEABIRD participants will be invited to participate regardless of their cognitive status
Exclusion
- Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment
- Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection
- Taking a disease-modifying drug for AD at time of enrollment
- Blood transfusion in the last three months
- Unwilling or unable to participate in all study activities
Key Trial Info
Start Date :
August 14 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT06547099
Start Date
August 14 2024
End Date
December 1 2028
Last Update
February 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110